<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817761</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-95015-001</org_study_id>
    <nct_id>NCT04817761</nct_id>
  </id_info>
  <brief_title>Calaspargase Pegol in Adults With ALL</brief_title>
  <official_title>A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To &gt;65 Years With Newly-diagnosed Philadelphia-negative ALL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the&#xD;
      safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with&#xD;
      Philadelphia-negative Acute Lymphoblastic Leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 parts. Part 1 is a dose confirmation run-in period. Part 2&#xD;
      will enroll the remaining participants at the dose as confirmed in Part 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) (Part 1)</measure>
    <time_frame>From signing the ICF through 30 days after the Calaspargase pegol administration at Day 4 (or Day 5 or Day 6) in the Remission Induction phase.</time_frame>
    <description>Including Treatment-emergent adverse events (TEAEs), adverse events of special interests (AESI); laboratory tests; vital signs; serious adverse events (SAEs) and AE. AEs recoded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) (Part 2)</measure>
    <time_frame>From signing the ICF through 30 days after the last dose of the study drug in Delayed Intensification phase.</time_frame>
    <description>Including Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESI); laboratory tests; vital signs; serious adverse events (SAEs) and AEs. AEs recoded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Asparaginase Activity (PAA) level (Part 1)</measure>
    <time_frame>Days 4, 5, 6 (Remission Induction phase) for PAA samples. Days 11, 18, 25 (Remission Induction phase) for TDM samples.</time_frame>
    <description>Assessment of PAA in Part 1 is based on population modeling analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nadir Plasma Asparaginase Activity (NPAA) (Part 2)</measure>
    <time_frame>Day 64 (Remission Consolidation Phase).</time_frame>
    <description>NPAA level ≥0.1 U/mL 21 days after the Remission Consolidation Phase Day 43 dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Asparaginase Activity (PAA) level ≥0.1 U/mL at any time during Remission Induction phase and post- Remission Induction phase, respectively (Part 2)</measure>
    <time_frame>Days 4-5-6 &amp; 11-18-25 (Remission Induction); Days 15-16-43-44 &amp; 22-29-36-50-57-64 (Consolidation); Days 22-23 &amp; 29-36-43 (Interim Maintenance); Days 4-5,43-44 &amp; 11-18-25-50-57-64 (Delayed Intensification) for PAA &amp; TDM samples respectively.</time_frame>
    <description>Pharmacodynamics criterion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Asparaginase Activity (PAA) level ≥0.025, ≥0.1, ≥0.2, or ≥0.4 U/mL at predefined time points during Remission Induction phase and post- Remission Induction phase, respectively (Part 2)</measure>
    <time_frame>Days 4-5-6 &amp; 11-18-25 (Remission Induction); Days 15-16-43-44 &amp; 22-29-36-50-57-64 (Consolidation); Days 22-23 &amp; 29-36-43 (Interim Maintenance); Days 4-5-43-44 &amp; 11-18-25-50-57-64 (Delayed Intensification) for PAA &amp; TDM samples respectively.</time_frame>
    <description>Pharmacodynamics criterion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAA-derived maximum concentration (Cmax) after the Remission Induction Phase Day 4 dose (Part 1 and 2).</measure>
    <time_frame>Days 4, 5, 6 &amp; 11, 18, 25 (Remission Induction); for PAA &amp; TDM samples respectively.</time_frame>
    <description>PAA-derived Cmax are based on population modeling analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 21 (AUC 0-21) after the Remission Induction Phase Day 4 dose (Part 1 and 2).</measure>
    <time_frame>Days 4, 5, 6 &amp; 11, 18, 25 (Remission Induction); for PAA &amp; TDM samples respectively.</time_frame>
    <description>PAA-derived AUC 0-21 are based on population modeling analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) (Part 1 and 2)</measure>
    <time_frame>End of remission induction phase (Day 29).</time_frame>
    <description>Efficacy criterion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) (Part 1 and 2)</measure>
    <time_frame>Day 29 remission induction therapy</time_frame>
    <description>Morphologic complete remission rate (CR), morphologic complete remission rate with incomplete blood count recovery (CRi).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (Part 1 and 2)</measure>
    <time_frame>Through study completion an average of 3 months.</time_frame>
    <description>1-year EFS (event-free survival), DFS (disease-free survival) and OS (overall survival)&#xD;
2-year EFS, DFS, OS&#xD;
3-year EFS, DFS, OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug (calaspargase pegol) antibody (ADA) development (Part 1 and 2)</measure>
    <time_frame>D4, D18, D29 (Remission Induction Phase), D15, D43 (Remission Consolidation Phase), D22 (Interim Maintenance Phase), D4, D43 (Delayed Intensification Phase), Day 365 (±7) after the first dose, Day 30 after the last dose if discontinuation.</time_frame>
    <description>Immunogenicity criterion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Calaspargase pegol (S95015)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calaspargase pegol (S95015)</intervention_name>
    <description>Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.&#xD;
Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.&#xD;
Part 2: S95015 will be administered at doses as confirmed in part 1.</description>
    <arm_group_label>Calaspargase pegol (S95015)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥22 years with newly-diagnosed and cytologically confirmed and documented&#xD;
             Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO)&#xD;
             classification (2016).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2.&#xD;
&#xD;
          -  No prior therapy for ALL such as chemotherapy and radiation therapy before signing the&#xD;
             informed consent except for limited treatment (≤7 days) with corticosteroids or&#xD;
             hydroxyurea and a single dose of intrathecal cytarabine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Philadelphia chromosome positive ALL, Burkitt's leukemia, mixed&#xD;
             lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia per WHO&#xD;
             classification (2016).&#xD;
&#xD;
          -  Patients with Down syndrome.&#xD;
&#xD;
          -  Patients with Hepatitis B (positive for HBs antigen), and Hepatitis C (HCV antibody)&#xD;
             at inclusion&#xD;
&#xD;
          -  Participants known to be HIV-positive.&#xD;
&#xD;
          -  Known history of non-gallstone-related pancreatitis.&#xD;
&#xD;
          -  Known severe hepatic impairment (bilirubin &gt;3 x upper limit of normal [ULN];&#xD;
             transaminases &gt;10 times ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. DeAngelo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute, Boston, MA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier, Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Cancer Transplant Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-323-1573</phone>
    </contact>
    <contact_backup>
      <phone>+1 480 882-5876</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>626-218-3279</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Health Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-822-6100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert H Lurie Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>626-218-3279</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-328-6841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>410-614-9106</phone>
    </contact>
    <contact_backup>
      <phone>+1 410 614 72</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone/Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-501-4818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-684-8964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-606-1202</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Ph-negative B-cell and T cell ALL</keyword>
  <keyword>Philadelphia-negative ALL</keyword>
  <keyword>Calaspargase Pegol</keyword>
  <keyword>Asparlas</keyword>
  <keyword>Adult</keyword>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>Newly diagnosed ALL</keyword>
  <keyword>Untreated ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

